XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Common Stock | 12 Months Ended
--- | ---
Dec. 31, 2024
Equity [Abstract] |
Common Stock | 12. Common Stock In February 2020, the Company entered into the Open Market Sale Agreement (as amended on each of March 4, 2022 and August 9, 2024, the “Sales Agreement”) with Jefferies LLC (“Jefferies”), to sell its common stock, at par value $0.00001 per share, with aggregate gross sales proceeds of up to $75,000,000, from time to time upon the Company’s request, through an at-the-market ("ATM") offering under which Jefferies will act as sales agent. Pursuant to the Sales Agreement, Jefferies as the sales agent will receive a commission of 3.0% of the gross sales price for shares of common stock sold under the Sales Agreement. In April 2024, under the Sales Agreement, the Company sold 2,270,608 shares at an average price of $2.20 per share and received net proceeds of approximately $4.8 million after deducting the 3.0% sales commission and related issuance cost. In December 2024, the Company sold 1,654,594 shares at an average price of $1.3 per share under the ATM offering and received net proceeds of approximately $2.1 million after deducting the 3.0% sales commission and related issuance cost. In June 2023, the Company entered into an agreement with BVF Partners L.P. (“BVF”) for a private placement and received an aggregate net proceeds of approximately $29.7 million in July 2023, after deducting issuance costs of approximately $0.3 million. In the private placement, CytomX issued pre-funded warrants to BVF to purchase up to 14,423,077 shares of common stock, accompanying Tranche 1 warrants to purchase up to 5,769,231 shares of common stock and accompanying Tranche 2 warrants to purchase up to 5,769,231 shares of common stock, at a combined price of $2.08 per share. In May 2024, BVF exercised its right to purchase 7.5 million shares of common stock through its pre-funded warrants at an exercise price of $0.00001 per share. The following table summarizes the Company's warrants activities:
|  | Pre-funded Warrants |  |  | Tranche 1 Warrants |  |  | Tranche 2 Warrants |
|  | Number of warrants |  |  | Weighted- Average Exercise Price Per Share |  |  | Number of warrants |  |  | Weighted- Average Exercise Price Per Share |  |  | Number of warrants |  |  | Weighted- Average Exercise Price Per Share |
Balance at December 31, 2023 |  |  | 14,423,077 |  |  | $ | 0.00001 |  |  |  | 5,769,231 |  |  | $ | 4.16 |  |  |  | 5,769,231 |  |  | $ | 6.24 |
Exercises |  |  | (7,500,000 | ) |  |  |  |  |  | — |  |  |  |  |  |  | — |  |  |  |
Balance at December 31, 2024 |  |  | 6,923,077 |  |  | $ | 0.00001 |  |  |  | 5,769,231 |  |  | $ | 4.16 |  |  |  | 5,769,231 |  |  | $ | 6.24 |
The pre-funded warrants will expire in July 2043, while Tranche 1 and Tranche 2 warrants will expire in July 2025 and July 2026, respectively. In the May 2024 annual meeting of stockholders, the Company's authorized shares of common stock were approved to increase from 150,000,000 shares to 300,000,000 shares.

X
- Definition Common stock. + References No definition available. + Details
Name: | ctmx_CommonStockTextBlock
Namespace Prefix: | ctmx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration